Brief: Tempest Reports Positive Tpst-1120 Clinical Data From Phase 1 Trial In Patients With Advanced Solid Tumors At 2022 Asco Annual Meeting
27/05/2022 24:36
May 26 (Reuters) - Tempest Therapeutics Inc TPST.O :
* TEMPEST REPORTS POSITIVE TPST-1120 CLINICAL DATA FROM
PHASE 1
TRIAL IN PATIENTS WITH ADVANCED SOLID TUMORS AT 2022 ASCO ANNUAL
MEETING
* TEMPEST THERAPEUTICS INC - RECIST RESPONSES OBSERVED IN
IO-REFRACTORY PATIENTS AND IN IO-RESISTANT INDICATIONS
* TEMPEST THERAPEUTICS INC - TPST-1120 WAS WELL-TOLERATED
BOTH AS
A MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB
* TEMPEST THERAPEUTICS INC - RANDOMIZED GLOBAL PHASE 1B/2
STUDY IS
ONGOING IN PREVIOUSLY UNTREATED PATIENTS WITH HEPATOCELLULAR
CARCINOMA
Source text for Eikon: ID:nGNXpGRKG
Further company coverage: TPST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T